Liver fibrosis represents a significant and escalating health concern globally, being a key pathological feature of chronic liver diseases (CLDs). It arises from sustained liver injury due to factors such as viral hepatitis, alcohol abuse, or non-alcoholic fatty liver disease. Without timely intervention, fibrosis can progress to irreversible damage, manifesting as cirrhosis, liver cancer, or even liver failure. These advanced stages substantially increase morbidity and mortality rates, underscoring the urgent need for effective therapeutic strategies. Central to the development and progression of liver fibrosis is the dysregulation of metabolic pathways, including glycolysis—a critical process that provides energy and biosynthetic precursors to activated liver cells. Current pharmacological approaches remain limited and largely palliative, emphasizing the importance of exploring innovative treatments that target specific mechanisms driving fibrosis. Among the promising avenues is the inhibition of liver sinusoidal endothelial cell (LSEC) glycolysis, which has shown potential to reduce chemokine secretion and attenuate inflammation, key contributors to fibrogenesis.
Quercetin: A Natural Ally
Quercetin, a plant-derived flavonoid present in various fruits and vegetables, has gained recognition for its diverse pharmacological properties, including antioxidant, anti-inflammatory, and anti-fibrotic effects. Recent preclinical studies have shed light on its capacity to modulate glycolysis, a metabolic pathway intimately involved in the progression of liver fibrosis. By downregulating key glycolytic enzymes, such as hexokinase II (HK2), phosphofructokinase platelet (PFKP), and pyruvate kinase M2 (PKM2), quercetin effectively reduces the energy supply needed for fibrotic processes, particularly in LSECs. Additionally, quercetin inhibits the secretion of chemokines like CXCL1, thereby diminishing neutrophil infiltration—a key driver of inflammation and fibrosis. These dual mechanisms position quercetin as a promising candidate for liver fibrosis therapy, potentially addressing both metabolic dysregulation and inflammatory cascades. Further research into its clinical application could transform the current therapeutic landscape, offering a natural and targeted approach to combating this debilitating condition.
Findings
A study conducted by Chen et al. explored the role of quercetin in liver fibrosis. Using a mouse model treated with carbon tetrachloride (CCl4) to induce fibrosis, the researchers administered varying doses of quercetin and monitored its effects. Key findings include:
Reduced Liver Injury: Quercetin lowered elevated levels of key liver enzymes and markers like ALT, AST, and total bile acid.
Fibrosis Alleviation: Pathological analysis showed decreased collagen deposition, supported by reduced levels of fibrosis markers such as hyaluronic acid and procollagen type III.
Regulation of Glycolysis: Quercetin significantly inhibited glycolysis in liver sinusoidal endothelial cells (LSECs), reducing the production of lactate, glucose consumption, and expression of glycolytic enzymes like hexokinase II and pyruvate kinase M2.
Reduced Inflammation: By suppressing the chemokine CXCL1, quercetin curtailed neutrophil infiltration—a critical driver of liver fibrosis.
Practical Outcomes of Research
This research highlights quercetin’s potential as a therapeutic agent for liver fibrosis by addressing core disease mechanisms. By inhibiting LSEC glycolysis, quercetin disrupts the metabolic processes fueling fibrosis, downregulating key glycolytic enzymes such as hexokinase II (HK2) and pyruvate kinase M2 (PKM2). This reduces energy production critical for fibrosis progression.
Additionally, quercetin curbs inflammation by lowering CXCL1 secretion, which diminishes neutrophil infiltration—a major contributor to liver damage and portal vein pressure. By targeting both metabolic dysregulation and inflammation, quercetin offers a dual-action approach, positioning it as a promising candidate to combat liver fibrosis beyond symptom relief.
What’s Next?
While the findings are promising, further clinical trials are needed to confirm the safety and efficacy of quercetin in humans. If successful, this natural compound could be a game-changer in managing liver fibrosis and other metabolic diseases.
For researchers and healthcare professionals, quercetin opens a new avenue of inquiry. Its dual role in metabolic regulation and immune response modulation highlights its therapeutic versatility.
The translation of the preceding English text in Chinese:
Leave a Reply